AI Terminal
Active Biotech
Declaration of Voting Results & Voting Rights Announcements • Jan 31, 2025
3133_rns_2025-01-31_5c6defa8-9621-4568-b82e-67bb61a6947d.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Number of shares and votes in Active Biotech
The number of shares and votes in Active Biotech AB (publ) has changed as a result of the recently completed rights issue. The 164,638,960 shares in relation to which allotment was conditional on that relevant FDI (Foreign Direct Investment) approvals from the Inspectorate of Strategic Products, have been registered in January.
Today, the last trading day of the month, there are in total 1,230,164,682 shares and votes in Active Biotech.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, [email protected] Hans Kolam, CFO, +46 46 19 20 44, [email protected]
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops firstin-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies has been initiated. Also ongoing is a clinical Phase Ib/IIa study in multiple myeloma. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation is ongoing to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www. activebiotech.com for more information.
This information is information that Active Biotech is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-01-31 08:30 CET.